BTIG Maintains Buy on Treace Medical Concepts, Lowers Price Target to $27.5
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has maintained a 'Buy' rating on Treace Medical Concepts (NASDAQ:TMCI) but lowered the price target from $32 to $27.5.

August 28, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BTIG analyst has maintained a 'Buy' rating on Treace Medical Concepts but lowered the price target from $32 to $27.5.
The news is directly related to Treace Medical Concepts. While the 'Buy' rating is maintained, the lowering of the price target might indicate a potential slowdown in growth or increased risk, which could have a neutral to slightly negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100